Kura Downgraded to Hold by Stifel, Prefers Rival Syndax
This Caterpillar Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Stifel Downgrades Kura Oncology(KURA.US) to Hold Rating, Cuts Target Price to $19
Stifel Downgrades Kura Oncology to Hold From Buy, Adjusts Price Target to $19 From $26
Kura Oncology Reports 'Encouraging' Results From Trial of Potential Leukemia Treatment
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
Press Release: Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors
Kura Oncology to Participate in Cantor Global Healthcare Conference
Kura Oncology, Inc. (KURA): This Small-Cap Healthcare Stock Is A Good Buy Right Now
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA), Tenaya Therapeutics (TNYA) and PepGen Inc. (PEPG)
HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target
Kura Oncology Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Aquestive Therapeutics (AQST)
Wedbush Reiterates Outperform on Kura Oncology, Maintains $37 Price Target
Kura Oncology Is Maintained at Buy by Stifel
Scotiabank Reaffirms Their Hold Rating on Kura Oncology (KURA)
Buy Rating Affirmed for Kura Oncology Amid Positive Clinical and Financial Developments
Express News | Kura Oncology Inc : Stifel Cuts Target Price to $26 From $28
Positive Outlook for Kura Oncology as Ziftomenib Shows Promise in AML Treatment and Expands Clinical Trials
Express News | Kura Oncology Inc: $491.5 Mln in Cash, Cash Equivalents and Investments Provide Runway Into 2027